Trial reportAnnals of the rheumatic diseases2007
How do the EQ-5D, SF-6D and the well-being rating scale compare in patients with ankylosing spondylitis?
Trial report in Annals of the rheumatic diseases, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Construct Validity and Responsiveness of EQ-5D-3L in Patients With Rheumatic Disease
Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Health state utility values in patients with Ankylosing Spondylitis: a systematic review and meta-analysis.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024Pooled it
- The validity and reliability of quality of life questionnaires in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and meta-analysis.Health and quality of life outcomes · 2022Pooled it
- Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review.Health and quality of life outcomes · 2020Pooled it
- Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country.Frontiers in pharmacology · 2019Pooled it
- Tripterygium wilfordii Hook F. in the treatment of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a clinical trial.Clinical rheumatology · 2021Trial
- Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.Annals of the rheumatic diseases · 2016Trial
- Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis.Arthritis research & therapy · 2009Trial
- The value of EQ-5D-3L and EQ VAS as a patient-reported outcome measure for patients with ankylosing spondylitis in routine healthcare: an evaluation of construct validity and responsiveness based on the Swedish Rheumatology Quality Register.Journal of patient-reported outcomes · 2026Article
- Development of a Physiotherapist-Coordinated Interdisciplinary Rehabilitation Intervention for People with Suspected Axial Spondyloarthritis: The SPINCODE Rehabilitation Intervention.Journal of clinical medicine · 2024Article
- Comparative performance and mapping algorithms between EQ-5D-5L and SF-6Dv2 among the Chinese general population.The European journal of health economics : HEPAC : health economics in prevention and care · 2024Article
- Potential Mechanism of Fatigue Induction and Its Management by JAK Inhibitors in Inflammatory Rheumatic Diseases.Journal of inflammation research · 2023Review
- Comparison of EuroQol-5D-3L and Short Form-6D Utility Scores in Family Caregivers of Colorectal Cancer Patients: A Cross-Sectional Survey in China.Frontiers in public health · 2021Article
- Interchangeability of the EQ-5D and the SF-6D, and comparison of their psychometric properties in a spinal postoperative Spanish population.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- Patient Burden of Axial Spondyloarthritis.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2017Review
- Valuing benefits to inform a clinical trial in pharmacy : do differences in utility measures at baseline affect the effectiveness of the intervention?PharmacoEconomics · 2013Article
- Deriving reference values and utilities for the QoL-AGHDA in adult GHD.The European journal of health economics : HEPAC : health economics in prevention and care · 2011Article
- Preoperative risk assessment for bleeding and thromboembolism.BMJ (Clinical research ed.) · 2009Article
- Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis.BMJ (Clinical research ed.) · 2009Review
- Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2009Article
- Variables related to utility in patients with ankylosing spondylitis.Clinical rheumatology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare aspects of validity of EuroQol-5 Dimensions (EQ-5D) and Short-Form-6 Dimensions (SF-6D), two indirect utility instruments, and the well-being rating scale (RS) in ankylosing spondylitis (AS).
methodsEQ-5D, SF-6D and RS were available for 254 patients fulfilling modified New York criteria. 134 patients were part of an observational cohort and 120 were part of a randomised controlled trial (RCT). Aspects of validity assessed were truth (agreement and correlation with external health measures) and discrimination (differentiation between health states, repeatability and detection of treatment effect).
resultsMedian (range) values were 0.69 (-0.08-1.00) for the EQ-5D, 0.65 (0.35-0.95) for the SF-6D and 0.65 (0.14-1.00) for the RS. Agreement (intraclass correlation coefficient) was moderate (0.46-0.55). Instruments correlated equally with disease activity, functioning and quality of life. The SF-6D showed smaller average differences in utility between patients with better and worse disease compared with the EQ-5D and the RS. The smallest detectable difference (SDD) (in the control group of RCT) was 0.36, 0.17 and 0.33 for EQ-5D, SF-6D and RS, respectively. The ability to detect treatment effect (in the intervention trial) showed standardised effect sizes that were moderate for EQ-5D and SF-6D (0.63 and 0.64) and low for the RS (0.23).
conclusionIn patients with AS, EQ-5D, SF-6D and the RS correlate equally well with external measures of health, but have different psychometric properties. The SDD is most favourable for the SF-6D, but it discriminates less well between patients with different disease severities. The RS has a poorer ability to detect treatment effects. It is difficult to recommend one of the instruments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.